Philadelphia Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Philadelphia Pharmaceuticals's earnings have been declining at an average annual rate of -12.4%, while the Pharmaceuticals industry saw earnings growing at 11.4% annually. Revenues have been declining at an average rate of 1.2% per year. Philadelphia Pharmaceuticals's return on equity is 6.3%, and it has net margins of 9.6%.
Key information
-12.4%
Earnings growth rate
-12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -1.2% |
| Return on equity | 6.3% |
| Net Margin | 9.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Philadelphia Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8 | 1 | 2 | 0 |
| 30 Sep 23 | 8 | 1 | 2 | 0 |
| 30 Jun 23 | 9 | 1 | 2 | 0 |
| 31 Mar 23 | 8 | 1 | 3 | 0 |
| 31 Dec 22 | 8 | 1 | 3 | 0 |
| 30 Sep 22 | 8 | 1 | 3 | 0 |
| 30 Jun 22 | 7 | 1 | 3 | 0 |
| 31 Mar 22 | 7 | 1 | 2 | 0 |
| 31 Dec 21 | 7 | 0 | 2 | 0 |
| 30 Sep 21 | 6 | 0 | 2 | 0 |
| 30 Jun 21 | 6 | 0 | 3 | 0 |
| 31 Mar 21 | 7 | 0 | 3 | 0 |
| 31 Dec 20 | 8 | 0 | 3 | 0 |
| 30 Sep 20 | 9 | 1 | 3 | 0 |
| 30 Jun 20 | 9 | 1 | 3 | 0 |
| 31 Mar 20 | 9 | 1 | 3 | 0 |
| 31 Dec 19 | 9 | 1 | 3 | 0 |
| 30 Sep 19 | 9 | 1 | 3 | 0 |
| 30 Jun 19 | 8 | 1 | 3 | 0 |
| 31 Mar 19 | 8 | 1 | 3 | 0 |
| 31 Dec 18 | 8 | 1 | 2 | 0 |
| 30 Sep 18 | 8 | 1 | 2 | 0 |
| 30 Jun 18 | 8 | 1 | 2 | 0 |
| 31 Mar 18 | 8 | 1 | 2 | 0 |
| 31 Dec 17 | 7 | 1 | 2 | 0 |
| 30 Sep 17 | 7 | 1 | 2 | 0 |
| 30 Jun 17 | 6 | 1 | 2 | 0 |
| 31 Mar 17 | 6 | 0 | 3 | 0 |
| 31 Dec 16 | 7 | 1 | 3 | 0 |
| 30 Sep 16 | 7 | 1 | 3 | 0 |
| 30 Jun 16 | 8 | 1 | 3 | 0 |
| 31 Mar 16 | 10 | 2 | 3 | 0 |
| 31 Dec 15 | 10 | 3 | 3 | 0 |
| 30 Sep 15 | 11 | 3 | 3 | 0 |
| 30 Jun 15 | 11 | 3 | 2 | 0 |
| 31 Mar 15 | 11 | 3 | 2 | 0 |
| 31 Dec 14 | 10 | 3 | 2 | 0 |
| 30 Sep 14 | 10 | 3 | 2 | 0 |
| 30 Jun 14 | 9 | 3 | 2 | 0 |
| 31 Mar 14 | 7 | 2 | 2 | 0 |
| 31 Dec 13 | 4 | 1 | 1 | 0 |
| 30 Sep 13 | 3 | 0 | 1 | 0 |
| 30 Jun 13 | 2 | 0 | 1 | 0 |
Quality Earnings: PHIL has high quality earnings.
Growing Profit Margin: PHIL's current net profit margins (9.6%) are higher than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHIL's earnings have declined by 12.4% per year over the past 5 years.
Accelerating Growth: PHIL's earnings growth over the past year (15.1%) exceeds its 5-year average (-12.4% per year).
Earnings vs Industry: PHIL earnings growth over the past year (15.1%) exceeded the Pharmaceuticals industry 8%.
Return on Equity
High ROE: PHIL's Return on Equity (6.3%) is considered low.